Ex vivo 3D cell culture tech makes ‘true drug response prediction’ possible: KIYATEC

19-Aug-2019 By Maggie Lynch

Capital Health joins Kiyatec’s clinical trial to validate a patient-specific predictor test to improve response to cancer therapies for glioblastoma and anaplastic astrocytoma. 

HTTPS://WWW.OUTSOURCING-PHARMA.COM/ARTICLE/2019/08/19/EX-VIVO-3D-CELL-CULTURE-TECH-MAKES-TRUE-DRUG-RESPONSE-PREDICTION-POSSIBLE-KIYATEC